Skip to main content
NCBI home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 1986;97:43–52.

A rational scientific basis for subclassification of antiarrhythmic drugs.

D C Harrison
PMCID: PMC2279697  PMID: 3837966

Abstract

The subclassification of Vaughan Williams Class I agents into IA, IB, and IC groups on empiric and clinical grounds has recently been given a cellular electrophysiologic scientific basis. Based on the kinetics of association and dissociation of the drugs with sodium channels, 3 distinct subgroups can be defined. These observations help to explain the clinical utility of the algorithms to use the agents in patients and provide a reference for discussing the new drugs with antiarrhythmic properties being discovered.

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell T. J. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983 Jun;17(6):344–352. doi: 10.1093/cvr/17.6.344. [DOI] [PubMed] [Google Scholar]
  2. Campbell T. J., Vaughan Williams E. M. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res. 1983 May;17(5):251–258. doi: 10.1093/cvr/17.5.251. [DOI] [PubMed] [Google Scholar]
  3. Carey E. L., Jr, Duff H. J., Roden D. M., Primm R. K., Wilkinson G. R., Wang T., Oates J. A., Woosley R. L. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest. 1984 Feb;73(2):539–547. doi: 10.1172/JCI111241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Courtney K. R. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther. 1975 Nov;195(2):225–236. [PubMed] [Google Scholar]
  5. Harrison D. C. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol. 1985 Jul 1;56(1):185–187. doi: 10.1016/0002-9149(85)90591-0. [DOI] [PubMed] [Google Scholar]
  6. Hondeghem L., Katzung B. G. Test of a model of antiarrhythmic drug action. Effects of quinidine and lidocaine on myocardial conduction. Circulation. 1980 Jun;61(6):1217–1224. doi: 10.1161/01.cir.61.6.1217. [DOI] [PubMed] [Google Scholar]
  7. Keefe D. L., Kates R. E., Harrison D. C. New antiarrhythmic drugs: their place in therapy. Drugs. 1981 Nov;22(5):363–400. doi: 10.2165/00003495-198122050-00002. [DOI] [PubMed] [Google Scholar]
  8. Mandelkorn J. B., Wolf N. M., Singh S., Shechter J. A., Kersh R. I., Rodgers D. M., Workman M. B., Bentivoglio L. G., LaPorte S. M., Meister S. G. Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. Am J Cardiol. 1983 Jul;52(1):1–6. doi: 10.1016/0002-9149(83)90059-0. [DOI] [PubMed] [Google Scholar]
  9. Vaughan Williams E. M. Disopyramide. Ann N Y Acad Sci. 1984;432:189–200. doi: 10.1111/j.1749-6632.1984.tb14520.x. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES